Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients

F. Ortíz-Sanjuán; Ricardo Blanco; V. Calvo-Río; Javier Narváez; E. Rubio Romero; Alejandro Olivé; Santos Castañeda; Adela Gallego Flores; M.V. Hernández; Cristina Mata; Inmaculada Ros Vilamajó; Walter Alberto Sifuentes Giraldo; Miguel A. Caracuel; Mercedes Freire; C. Gόmez Arango; José Llobet; Sara Manrique‐Arija; Carlos Marras; Concepción Moll‐Tuduri; Chamaida Plasencia‐Rodríguez; Rosa Roselló; Ana Urruticoechea; María Luisa Velloso-Feijoó; Jordi del Blanco; M. Carmen Gonzaléz‐Vela; Javier Rueda‐Gotor; Trinitario Pina; J. Loricera; Miguel Á. González‐Gay

doi:10.1002/art.38398

Abstract

TCZ treatment was associated with rapid and maintained clinical and laboratory improvement in patients with AOSD refractory to standard treatment. However, joint manifestations seem to be more refractory to treatment compared with systemic manifestations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ortíz-Sanjuán et al. (2014) studied this question.

synapsesocial.com/papers/69d8b17b17a1cc0598d17d82 https://doi.org/10.1002/art.38398

View Full Paper

Ask AI

Bookmark

Share

Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients

Abstract

Discussion

Cite This Study

Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients

Abstract

Discussion

Cite This Study

Keep reading

Keep reading